Antimicrobial Susceptibility Testing Market by Product Type, Method, Type, Application, End-User

Description

List of Tables

The Antimicrobial Susceptibility Testing Market was valued at USD 3.81 billion in 2023, expected to reach USD 4.02 billion in 2024, and is projected to grow at a CAGR of 5.83%, to USD 5.67 billion by 2030.

Antimicrobial Susceptibility Testing (AST) is a critical component in infectious disease management, involving the determination of the efficacy of antibiotics on bacteria or fungi. The necessity of AST is underscored by the growing threats of antibiotic resistance, requiring timely and accurate information for effective antimicrobial therapy. Applications of AST are broad, encompassing clinical settings to guide appropriate treatment regimens, pharmaceutical research and development to screen for new antimicrobials, and public health surveillance to monitor resistance patterns. The end-use scope primarily involves hospitals, diagnostic labs, pharmaceutical companies, and research institutions. Market growth is influenced by factors such as increasing incidences of infectious diseases, rising awareness of antimicrobial resistance, advanced technological innovations in testing methods, and substantial government support. The latest potential opportunities lie in the development of rapid, automated AST systems, integration with genomic testing to enhance precision, and cloud-based platforms for data sharing and analysis. To capitalize on these, businesses should invest in research and development of user-friendly, cost-effective diagnostic solutions and enhance collaborations with healthcare providers and research bodies. However, market growth is hindered by challenges such as high costs of advanced AST systems, complex regulatory processes, and the limited accessibility in low-resource settings. Furthermore, variability in microbial response necessitates continuous updates and validation of testing methods. Innovation opportunities are abundant, particularly in the development of AI-driven predictive models and portable AST devices tailored for point-of-care use. Increased emphasis on personalized medicine also offers a promising avenue for AST innovation. The AST market exhibits a dynamic nature, with growth potential tightly linked to advancements in biotechnology and informatics, alongside evolving patterns in microbial resistance, necessitating continuous adaptation and proactive strategies to sustain and accelerate market development.

KEY MARKET STATISTICS
Base Year [2023]	USD 3.81 billion
Estimated Year [2024]	USD 4.02 billion
Forecast Year [2030]	USD 5.67 billion
CAGR (%)	5.83%

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Antimicrobial Susceptibility Testing Market

The Antimicrobial Susceptibility Testing Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

Market Drivers
- Importance of antimicrobial susceptibility testing in medical decision-making
- Favorable government initiatives aiming to combat and prevent infectious diseases
Market Restraints
- High cost of antimicrobial susceptibility kits and lack of skilled professionals
Market Opportunities
- Ongoing research on nanoparticles-based antimicrobial susceptibility testing
- Introduction of new genomic identification methods and launch of antimicrobial susceptibility test kits
Market Challenges
- Incidence of product recalls and strict regulations regarding antimicrobial susceptibility testing commercialization

Porter's Five Forces: A Strategic Tool for Navigating the Antimicrobial Susceptibility Testing Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Antimicrobial Susceptibility Testing Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Antimicrobial Susceptibility Testing Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Antimicrobial Susceptibility Testing Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Antimicrobial Susceptibility Testing Market

A detailed market share analysis in the Antimicrobial Susceptibility Testing Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Antimicrobial Susceptibility Testing Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Antimicrobial Susceptibility Testing Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Key Company Profiles

The report delves into recent significant developments in the Antimicrobial Susceptibility Testing Market, highlighting leading vendors and their innovative profiles. These include Creative Diagnostics, Bio-Rad Laboratories, Inc., Biosafe Ltd., BioMerieux SA, Laboratorios Conda, S.A., Genefluidics, Inc., Pfizer Inc., F. Hoffmann-La Roche AG, Danaher Corporation, Zhuhai DL Biotech Co., Ltd., Becton, Dickinson and Company, Launch Diagnostics Limited, Alifax S.r.l., Liofilchem S.r.l., Synoptics Group, QuantaMatrix Inc., Himedia Laboratories Private Limited, Mast Group Ltd., ELITech Group SAS, INTEGRA Biosciences AG, Eurofins Scientific SE, Accelerate Diagnostics, Inc., Thermo Fisher Scientific Inc., Rapid Test Methods Ltd., Erba Lachema s.r.o., Bruker Corporation, Leading Biology, Inc., BIOANALYSE TIbbi Malz. San. ve Tic. Ltd. Sti., MP Biomedicals, LLC, Resistell AG, and Qiagen N.V..

Market Segmentation & Coverage

This research report categorizes the Antimicrobial Susceptibility Testing Market to forecast the revenues and analyze trends in each of the following sub-markets:

Based on Product Type, market is studied across Automated Products, Consumables, and Manual Products. The Manual Products is further studied across Minimum Inhibitory Concentration (MIC) Strips, Susceptibility Discs, and Susceptibility Plates.
Based on Method, market is studied across Agar Dilution, Disks Diffusion, ETEST, Genotyping Methods, and Rapid Automation Method.
Based on Type, market is studied across Antibacterial Susceptibility Testing, Antifungal Susceptibility Testing, and Antiparasitic Susceptibility Testing.
Based on Application, market is studied across Clinical Diagnostics, Drug Discovery & Development, and Epidemiology.
Based on End-User, market is studied across Contract Research Organizations, Hospital & Diagnostic Centers, Pharmaceutical & Biotechnology, and Research & Academic Institutes.
Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Product Code: MRR-464C422F4BD3

1. Preface

1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders

2. Research Methodology

2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

5.1. Market Dynamics
- 5.1.1. Drivers
  - 5.1.1.1. Importance of antimicrobial susceptibility testing in medical decision-making
  - 5.1.1.2. Favorable government initiatives aiming to combat and prevent infectious diseases
- 5.1.2. Restraints
  - 5.1.2.1. High cost of antimicrobial susceptibility kits and lack of skilled professionals
- 5.1.3. Opportunities
  - 5.1.3.1. Ongoing research on nanoparticles-based antimicrobial susceptibility testing
  - 5.1.3.2. Introduction of new genomic identification methods and launch of antimicrobial susceptibility test kits
- 5.1.4. Challenges
  - 5.1.4.1. Incidence of product recalls and strict regulations regarding antimicrobial susceptibility testing commercialization
5.2. Market Segmentation Analysis
- 5.2.1. Product Type: Advancement in the automated tools and consumables for early diagnosing and treatment of the infectious diseases
- 5.2.2. Method: Development of qualitative AST techniques with increased accuracy of the tests
- 5.2.3. Type: Significant advancements in antifungal susceptibility testing due to heightened awareness of invasive fungal infections
- 5.2.4. Application: Rapid and extreme utilization of the AST in clinical diagnostics and drug discovery and development
- 5.2.5. End-User: Extensive use of AST in hospitals and diagnostic laboratories
5.3. Porter's Five Forces Analysis
- 5.3.1. Threat of New Entrants
- 5.3.2. Threat of Substitutes
- 5.3.3. Bargaining Power of Customers
- 5.3.4. Bargaining Power of Suppliers
- 5.3.5. Industry Rivalry
5.4. PESTLE Analysis
- 5.4.1. Political
- 5.4.2. Economic
- 5.4.3. Social
- 5.4.4. Technological
- 5.4.5. Legal
- 5.4.6. Environmental

6. Antimicrobial Susceptibility Testing Market, by Product Type

6.1. Introduction
6.2. Automated Products
6.3. Consumables
6.4. Manual Products
- 6.4.1. Minimum Inhibitory Concentration (MIC) Strips
- 6.4.2. Susceptibility Discs
- 6.4.3. Susceptibility Plates

7. Antimicrobial Susceptibility Testing Market, by Method

7.1. Introduction
7.2. Agar Dilution
7.3. Disks Diffusion
7.4. ETEST
7.5. Genotyping Methods
7.6. Rapid Automation Method

8. Antimicrobial Susceptibility Testing Market, by Type

8.1. Introduction
8.2. Antibacterial Susceptibility Testing
8.3. Antifungal Susceptibility Testing
8.4. Antiparasitic Susceptibility Testing

9. Antimicrobial Susceptibility Testing Market, by Application

9.1. Introduction
9.2. Clinical Diagnostics
9.3. Drug Discovery & Development
9.4. Epidemiology

10. Antimicrobial Susceptibility Testing Market, by End-User

10.1. Introduction
10.2. Contract Research Organizations
10.3. Hospital & Diagnostic Centers
10.4. Pharmaceutical & Biotechnology
10.5. Research & Academic Institutes

11. Americas Antimicrobial Susceptibility Testing Market

11.1. Introduction
11.2. Argentina
11.3. Brazil
11.4. Canada
11.5. Mexico
11.6. United States

12. Asia-Pacific Antimicrobial Susceptibility Testing Market

12.1. Introduction
12.2. Australia
12.3. China
12.4. India
12.5. Indonesia
12.6. Japan
12.7. Malaysia
12.8. Philippines
12.9. Singapore
12.10. South Korea
12.11. Taiwan
12.12. Thailand
12.13. Vietnam

13. Europe, Middle East & Africa Antimicrobial Susceptibility Testing Market

13.1. Introduction
13.2. Denmark
13.3. Egypt
13.4. Finland
13.5. France
13.6. Germany
13.7. Israel
13.8. Italy
13.9. Netherlands
13.10. Nigeria
13.11. Norway
13.12. Poland
13.13. Qatar
13.14. Russia
13.15. Saudi Arabia
13.16. South Africa
13.17. Spain
13.18. Sweden
13.19. Switzerland
13.20. Turkey
13.21. United Arab Emirates
13.22. United Kingdom

14. Competitive Landscape

14.1. Market Share Analysis, 2023
14.2. FPNV Positioning Matrix, 2023
14.3. Competitive Scenario Analysis
- 14.3.1. Strathclyde spin-out Microplate dx secures GBP 2.5 million in funding
- 14.3.2. Creative Diagnostics Announces New Antimicrobial Susceptibility Testing Services
- 14.3.3. Sysmex Launches World's First Point-of-Care Testing System in Europe to Detect Antimicrobial Susceptibility in Just 30 Minutes
- 14.3.4. Pattern Bioscience Secures USD 28.7 Million in Series C Financing
- 14.3.5. JMI Laboratories and bioMerieux Enter Antimicrobial Resistance Diagnostics Partnership
- 14.3.6. Gradientech Welcomes Investment From Commercial Partner
- 14.3.7. bioMerieux's Submits Vitek Reveal to FDA for Clearance
- 14.3.8. Selux Diagnostics Secures FDA Approval For Its Rapid Antibiotic Susceptibility Test
- 14.3.9. FDA clears rapid antibiotic susceptibility test
- 14.3.10. FASTinov Collaborates With Beckman Coulter Life Sciences To Bring Ultra-Rapid 2h-AST Disruptive Technology To Clinical Microbiology Laboratories
- 14.3.11. Resistell raises CHF 8.5 million to complete clinical trials for antibiotic susceptibility testing
- 14.3.12. Avails Medical, A Developer 0f Automated and Fully Electrical Antibiotic Susceptibility Testing (East) has Announced the Transition to The Next Phase of Its Carb-X Grant.
- 14.3.13. BD Enters Commercial Collaboration With Accelerate Diagnostics
- 14.3.14. Bio-Rad Acquires Curiosity Diagnostics

Companies Mentioned

1. Creative Diagnostics
2. Bio-Rad Laboratories, Inc.
3. Biosafe Ltd.
4. BioMerieux SA
5. Laboratorios Conda, S.A.
6. Genefluidics, Inc.
7. Pfizer Inc.
8. F. Hoffmann-La Roche AG
9. Danaher Corporation
10. Zhuhai DL Biotech Co., Ltd.
11. Becton, Dickinson and Company
12. Launch Diagnostics Limited
13. Alifax S.r.l.
14. Liofilchem S.r.l.
15. Synoptics Group
16. QuantaMatrix Inc.
17. Himedia Laboratories Private Limited
18. Mast Group Ltd.
19. ELITech Group SAS
20. INTEGRA Biosciences AG
21. Eurofins Scientific SE
22. Accelerate Diagnostics, Inc.
23. Thermo Fisher Scientific Inc.
24. Rapid Test Methods Ltd.
25. Erba Lachema s.r.o.
26. Bruker Corporation
27. Leading Biology, Inc.
28. BIOANALYSE TIbbi Malz. San. ve Tic. Ltd. Sti.
29. MP Biomedicals, LLC
30. Resistell AG
31. Qiagen N.V.